Patents by Inventor Erik Spek
Erik Spek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150059028Abstract: A new and distinct variety of hybrid rose plant named ‘SPESALLE’ characterized by an attractive red flower with sufficient stem length, disease resistance, and acceptable productivity for the production of commercial cut flowers. ‘SPESALLE’ is characterized by a large flower with deep colored, velvety textured red petals in a very regular spiral pattern. The center petals are at the same height with the petals farther away from the center of the flower tapering down from the relatively flat time. The foliage is a dark, glossy green with a shape similar the lemon leaves.Type: ApplicationFiled: August 26, 2013Publication date: February 26, 2015Applicant: SPEK ROSE BREEDING INTERNATIONAL B.V.Inventor: Erik SPEK
-
Patent number: 7977462Abstract: The invention discloses 482 novel phosphorylation sites identified in carcinoma and/or leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.Type: GrantFiled: April 18, 2008Date of Patent: July 12, 2011Assignee: Cell Signaling Technology, Inc.Inventors: Peter Hornbeck, Ailan Guo, Ting-Lei Gu, Klarisa Rikova, Albrecht Moritz, Charles Farnsworth, Matthew Stokes, Jian Yu, Erik Spek, Yu Li, Anthony Possemato, Jessica Cherry, Valerie Goss, Jeffrey Mitchell, John Rush, Corinne Michaud
-
Publication number: 20110045603Abstract: The invention discloses 990 novel phosphorylation sites identified in carcinoma and leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.Type: ApplicationFiled: April 20, 2010Publication date: February 24, 2011Applicant: CELL SIGNALING TECHNOLOGY, INC.Inventors: Ailan Guo, Albrecht Moritz, Anthony Possemato, Ting-Lei Gu, Jian Yu, Charles Lawrence Farnsworth, Corinne Michaud, Hong Ren, Jessica Ann Cherry, Jing Zhou, Valerie Lee Goss, Erik Spek, Yu Li, Meghan Ann Tucker, John Edward Rush, II, Matthew Stokes, Klarisa Rikova
-
Publication number: 20100173322Abstract: The invention discloses nearly 219 novel phosphorylation sites identified in signal transduction proteins and pathways underlying Anaplastic Large Cell Lymphoma (ALCL) involving the NPM-ALK translocation/fusion, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose.Type: ApplicationFiled: March 6, 2008Publication date: July 8, 2010Inventors: Roberto Polakiewicz, Ailan Guo, Albrecht Moritz, Kimberly Lee, Erik Spek, Charles Farnsworth, Francesco Boccalatte
-
Publication number: 20100151495Abstract: The invention discloses nearly 443 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human carcinoma, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Protein kinases (including Serine/Threonine dual specificity, and Tyrosine kinases), Adaptor/Scaffold proteins, Transcription factors, Phospoatases, Tumor supressors, Ubiquitin conjugating system proteins, Translation initiation complex proteins, RNA binding proteins, Apoptosis proteins, Adhesion proteins, G protein regulators/GTPase activating protein/Guanine nucleotide exchange factor proteins, and DNA binding/replication/repair proteins, as well as other protein types.Type: ApplicationFiled: February 29, 2008Publication date: June 17, 2010Inventors: Roberto Polakiewicz, Ailan Guo, Albrecht Moritz, Klarisa Rikova, Kimberly Lee, Erik Spek, Yu Li, Charles Farnsworth
-
Publication number: 20100129930Abstract: The invention discloses 351 novel phosphorylation sites identified in carcinoma, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.Type: ApplicationFiled: July 27, 2007Publication date: May 27, 2010Inventors: Roberto Polakewicz, Charles Farnsworth, Ailan Guo, Klarisa Rikova, Albrecht Moritz, Kimberly Lee, Erik Spek
-
Publication number: 20100129929Abstract: The invention discloses 349 novel phosphorylation sites identified in carcinoma, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.Type: ApplicationFiled: July 27, 2007Publication date: May 27, 2010Inventors: Roberto Polakewicz, Charles Farnsworth, Ailan Guo, Klarisa Rikova, Albrecht Moritz, Kimberly Lee, Erik Spek
-
Publication number: 20100129928Abstract: The invention discloses 347 novel phosphorylation sites identified in carcinoma, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.Type: ApplicationFiled: July 27, 2007Publication date: May 27, 2010Inventors: Roberto Polakewicz, Charles Farnsworth, Ailan Guo, Klarisa Rikova, Albrecht Moritz, Kimberly Lee, Erik Spek
-
Publication number: 20100120055Abstract: The invention discloses 318 novel phosphorylation sites identified in carcinoma, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.Type: ApplicationFiled: September 28, 2007Publication date: May 13, 2010Applicant: CELL SIGNALING TECHNOLOGY, INC.Inventors: Peter Hornbeck, Ailan Guo, Klarisa Rikova, Albrecht Moritz, Erik Spek, Anthony Possemato, Charles Farnsworth, Francesco Boccalatte, Jian Yu, Jefrey Mitchell, John Rush, Valerie Goss, Ting-Lei Gu, Yu Li, Matthew Stokes
-
Publication number: 20100093000Abstract: The invention discloses novel phosphorylation sites identified in carcinoma and/or leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.Type: ApplicationFiled: April 18, 2008Publication date: April 15, 2010Inventors: Jessica Cherry, Charles Farnsworth, Valerie L. Goss, Ting-Lei Gu, Ailan Guo, Peter Hornbeck, Yu Li, Albrecht Moritz, Anthony Possemato, Klarisa Rikova, Matthew Stokes, Jian Yu, Erik Spek, Corinne Michaud
-
Publication number: 20090305297Abstract: The invention discloses 397 novel phosphorylation sites identified in carcinoma and/or leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.Type: ApplicationFiled: June 6, 2008Publication date: December 10, 2009Inventors: Peter Hornbeck, Francesco Boccalatte, Charles Farnsworth, Valerie Goss, Ting-Lei Gu, Ailan Guo, Yu Li, Albrecht Moritz, Klarisa Rikova, Erik Spek, Matthew Stokes, Jian Yu
-
Publication number: 20090258442Abstract: The invention discloses nearly 474 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human carcinoma, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Kinase, Adaptor/Scaffold proteins, Phosphatase, G protein Regulator/Guanine Nucleotide Exchange Factors/GTPase Activating Proteins, Cytoskeleton Proteins, DNA Binding Proteins, Phospholipase, Receptor Proteins, Enzymes, DNA Repair/Replication Proteins, Adhesion Proteins, and Proteases, as well as other protein types.Type: ApplicationFiled: February 29, 2008Publication date: October 15, 2009Inventors: Roberto Polakiewicz, Ailan Guo, Albrecht Moritz, Klarisa Rikova, Kimberly Lee, Erik Spek, Yu Li, Charles Farnsworth
-
Publication number: 20090098581Abstract: The invention discloses 482 novel phosphorylation sites identified in carcinoma and/or leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.Type: ApplicationFiled: April 18, 2008Publication date: April 16, 2009Inventors: Peter Hornbeck, Ailan Guo, Ting-Lei Gu, Klarisa Rikova, Albrecht Moritz, Charles Farnsworth, Matthew Stokes, Jian Yu, Erik Spek, Yu Li, Anthony Possemato, Jessica Cherry, Valerie Goss, Jeffrey Mitchell, John Rush, Corinne Michaud
-
Publication number: 20090061459Abstract: The invention discloses nearly 443 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human carcinoma, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Protein kinases (including Serine/Threonine dual specificity, and Tyrosine kinases), Adaptor/Scaffold proteins, Transcription factors, Phospoatases, Tumor supressors, Ubiquitin conjugating system proteins, Translation initiation complex proteins, RNA binding proteins, Apoptosis proteins, Adhesion proteins, G protein regulators/GTPase activating protein/Guanine nucleotide exchange factor proteins, and DNA binding/replication/repair proteins, as well as other protein types.Type: ApplicationFiled: February 29, 2008Publication date: March 5, 2009Inventors: Roberto Polakiewicz, Ailan Guo, Albrecht Moritz, Klarisa Rikova, Kimberly Lee, Erik Spek, Yu Li, Charles Farnsworth
-
Publication number: 20090053831Abstract: The invention discloses 405 novel phosphorylation sites identified in carcinoma and/or leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.Type: ApplicationFiled: April 30, 2008Publication date: February 26, 2009Inventors: Peter Hornbeck, Ailan Guo, Ting-Lei Gu, Klarisa Rikova, Albrecht Moritz, Charles Farnsworth, Matthew Stokes, Jian Yu, Erik Spek, Yu Li, Valerie Goss, Francesco Boccalatte
-
Patent number: PP26522Abstract: A new and distinct variety of hybrid rose plant named ‘SPESALLE’ characterized by an attractive red flower with sufficient stem length, disease resistance, and acceptable productivity for the production of commercial cut flowers. ‘SPESALLE’ is characterized by a large flower with deep colored, velvety textured red petals in a very regular spiral pattern. The center petals are at the same height with the petals farther away from the center of the flower tapering down from the relatively flat time. The foliage is a dark, glossy green with a shape similar the lemon leaves.Type: GrantFiled: August 26, 2013Date of Patent: March 22, 2016Assignee: Spek Rose Breeding International B.V.Inventor: Erik Spek